Work will facilitate interdisciplinary study of feelings, emotions, moods, and other sensory experiences, as well as the development of treatments for mental disorders.
Researchers at the Icahn School of Medicine at Mount Sinai have identified a new approach to controlling bacterial infections. The findings were described in the February 6 online issue of Nature Structural & Molecular Biology.
The Guyana Ministry of Health, the Mount Sinai Health System and Hess Corporation have announced the reopening and expansion of pathology and laboratory services at Georgetown Public Hospital Corporation to promote early diagnosis of diseases that will enhance patient care and treatment
The Windreich Department of Artificial Intelligence (AI) and Human Health at the Icahn School of Medicine at Mount Sinai announced a transformative $1.95 million gift from Schmidt Sciences to create The Eric and Wendy Schmidt AI in Human Health Fellowship Program.
Mount Sinai Health System leaders will attend and present at Arab Health 2024, the Middle East’s largest healthcare exhibition and congress, on January 29 – February 1
Tisch Cancer Institute researchers discovered that a certain type of chemotherapy improves the immune system’s ability to fight off bladder cancer, particularly when combined with immunotherapy, according to a study published in Cell Reports Medicine in January.
The Icahn School of Medicine at Mount Sinai has been awarded a grant of more than $4 million from The Leona M. and Harry B. Helmsley Charitable Trust to support an innovative research project aimed at understanding the early stages of Crohn’s disease before noticeable symptoms develop.
New York, NY [January 4, 2023]—In a milestone study, researchers from the Icahn School of Medicine at Mount Sinai have harnessed the power of artificial intelligence (AI) to enhance the assessment of the heart’s right ventricle, which sends blood to the lungs.
Mount Sinai researchers have shown for the first time that a person’s beliefs related to drugs can influence their own brain activity and behavioral responses in a way comparable to the dose-dependent effects of pharmacology.
Driven by the need for a better way to prioritize targets for drug development, the Icahn School of Medicine at Mount Sinai has led the development of a novel “genetic priority score” (GPS) that will integrate various types of human genetic data into a single easy-to-interpret score. The findings were described in the January 3 online issue of Nature Genetics [DOI: 10.1038/s41588-023-01609-2].
Studies have shown that drugs have an increased likelihood of success in clinical trials when the genes they target have been demonstrated to have genetic support. The new tool integrates multiple lines of genetic evidence to prioritize these drug targets.
Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenapine, a possible therapeutic target for substance use and neuropsychiatric disorders. This discovery may pave the way for the development of improved medications targeting the same pathway. Their findings, detailed in the January 2 online issue of Nature Communications https://doi.org/10.1038/s41467-023-44601-4, show that a brain protein known as the TAAR1 receptor, a drug target known to regulate dopamine signaling in key reward pathways in the brain, differs significantly in humans compared to the preclinical rodent models on which drugs are typically tested. The study suggests considering species-specific differences in drug-receptor interactions and further investigation into ways asenapine affects the body, as steps toward potential therapeutic improvements.
A team of health equity researchers from several institutions has leveraged a complex web of data to test a hypothesis: That structural racism is associated with resources and structures at the neighborhood level that are closely associated with poor health.
Patient-specific mutation-engineered mouse reveals how sensory neurons may trigger some allergy conditions but block others, suggesting more precise design of JAK inhibitors is necessary.
Prestigious grant will allow the New York City Virus Hunters initiative to expand an ongoing collaboration with BioBus that enables young students to keep city safe and help avoid future pandemics.
In a novel study, researchers from the Icahn School of Medicine at Mount Sinai introduced LoGoFunc, an advanced computational tool that predicts pathogenic gain- and loss-of-function variants across the genome.
Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC). And in an early parallel study in humans, combining immunotherapy with dupilumab—an Interleukin-4 (IL-4) receptor-blocking antibody widely used for treating allergies and asthma—boosted patients' immune systems, with one out of the six experiencing significant tumor reduction. The findings were described in the December 6 issue of Nature.
A new analysis of the brain activity of people with post-traumatic stress disorder (PTSD) is the first to reveal that traumatic memories are represented in the brain in an entirely different way than sad autobiographical memories.
The Icahn School of Medicine at Mount Sinai has been awarded a $3.2 million grant to support a free summer program for disadvantaged students interested in a career in medicine. The Health Resources and Services Administration, part of the U.S. Department of Health and Human Services, provided the five-year training grant.
A common concern about gender-affirming hormone therapy for transmasculine people is the risk of red blood cell volume changes and erythrocytosis, a high concentration of red blood cells, with the use of prescribed testosterone. However, Mount Sinai researchers have found that testosterone treatment may be safer than previously reported.
The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.
Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed “prognostic modules,” that significantly influence the progression of 32 different types of cancer. The study, published in Genome Research, serves as a comprehensive resource and lays the foundation for the development of next-generation cancer treatments and diagnostic markers.
New 5-year contracts for the Mid-Hudson Valley and New York City region support continued clinical services, outreach, and education to injured and sick workers.
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening drastically improves its cure rate measured over a 20-year period, according to a large-scale international study by Mount Sinai researchers published in Radiology.
Mount Sinai researchers have shed valuable light on the mechanism of a key protein that regulates the plasticity and function of the hippocampus, a key brain region involved in memory and learning, and that decreases with age in mice.
The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.
The Mount Sinai Hospital has been named No. 1 in New York State by Newsweek/Statista “America’s Best In-State-Hospitals” list for 2024 and the Mount Sinai Morningside ranked No. 15 on the same list.
The Icahn School of Medicine at Mount Sinai will award its 2023 Maria I. New International Prize for Biomedical Research to Jean-Laurent Casanova, MD, PhD, for revolutionizing our understanding of human infectious diseases through the discovery of genetic and immunological determinants that underpin both rare and common infectious illnesses. The prize honors medical pioneers in the tradition of Maria I. New, MD, a world-renowned researcher in pediatric genetic disorders with a special focus on endocrinology over her six-decade career. Dr. Casanova will receive a prize of $20,000 and will present the Maria I. New Distinguished Lecture during a ceremony to be held in at Icahn Mount Sinai in New York City on November 21, 2023.
The largest brain autopsy study of women who had experienced intimate partner violence reveals substantial vascular and white matter damage in the brain, but no evidence of chronic traumatic encephalopathy (CTE), the neurodegenerative disease recognized among male contact sports athletes who sustain repeated head trauma.